At the 10th European Stroke Organisation Conference (ESOC), PHRI researchers made significant contributions by presenting their impactful research on stroke prevention and treatment.
PHRI Senior Scientist Ashkan Shoamanesh shared new insights from PHRI’s large international ARTESiA trial which revealed that patients with device-detected subclinical atrial fibrillation and a history of previous stroke have a higher risk of stroke. The research recommends using apixaban for secondary prevention in these patients.
PHRI Scientist Mike Sharma, alongside Shoamanesh and Senior Scientist John Eikelboom, engaged in a panel discussion on Factor XIa inhibition. Sharma also presented findings from the AXIOMATIC-SSP trial and discussed the design of the OCEANIC-Stroke trial during a poster session. Additionally, Sharma shared predictors of thrombotic events in patients treated with Andexanet alfa, based on a pooled analysis of treated participants in the ANNEXa-4 and ANNEXa-I trials.
If at #ESOC2024 ensure to join myself, @mike_sharma2, @caso_valeria, @HanneKChr & @johneikelboom at our symposium focused on FXIa inhibition for secondary stroke prevention this afternoon. #stroke #neurotwitter @MacDeptMed @PHRIresearch @McmasterStroke pic.twitter.com/JHj6uQoTSy
— Ashkan Shoamanesh (@Ash_Shoamanesh) May 15, 2024
Concurrently, the results of the ANNEXa-I trial, led by PHRI Senior Scientist Stuart Connolly, were published in NEJM. The study revealed that the factor Xa inhibitor reversal agent andexanet reduced the expansion of intracerebral hemorrhages caused by factor Xa inhibitors but resulted in more thrombotic events than usual care.
Benz presenting on the INVICTUS trial
PHRI International Research Fellow Alexander P. Benz presented findings from the INVICTUS trial, exploring predictors of stroke in patients with atrial fibrillation associated with rheumatic heart disease. PHRI Investigator Aristeidis Katsanos presented in a session about the LAAOS III trial which found that surgical left atrial appendage occlusion (LAAO) during cardiac surgery prevents ischemic strokes in patients with atrial fibrillation.
Katsanos also presented posters on the ENRICH-AF global randomized trial and the CoVasc-ICH trial. The latter received the best research proposal award at the 1st ESO ICH Academy Meeting. CoVasc-ICH was among two selected research projects on ICH that received a grant of 10,000 Euros from ESO.
#CoVascICH received a best research proposal award at the 1st ESO ICH Academy Meeting. Congrats to the organizers of the event and all presenters! Many thanks to my coPI @Ash_Shoamanesh and all CoVasc-ICH investigators @ESOstroke #ESOC2024 @PHRIresearch pic.twitter.com/zJQAMcs0Do
— Aristeidis Katsanos (@ArKatsanos) May 15, 2024
ESO Scientific Excellence Award 2024
At ESOC 2024, Shoamanesh was awarded the prestigious ESO Scientific Excellence Award 2024 for his remarkable contributions to stroke research.
Shoamanesh honored with the ESO Scientific Excellence Award 2024
